RPS6KB1 and neoplasm: In this study, we identified a non‐canonical Raf‐1/p70S6K signalling pathway in NSCLC where Raf‐1 targets p70S6K as its downstream effector to regulate NSCLC tumour growth via sustaining proliferation, inhibiting apoptosis and promoting cell cycle progression (Figure 6).